Jubilant Pharmova Q1 Review - Near Term Challenges Dampen Quarterly Results: Nirmal Bang
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Jubilant Pharmova Ltd.’s Q1 FY23 performance was marred by a sharp decline across all the parameters. Generics and contract development and manufacturing organisation businesses saw a sharp decline in sales because of a steep drop in sartan prices, an unplanned shutdown of plant in Q4 FY22 (which led to some rollover effect in Q1 FY23, leading to lower volume), import alert on the Roorkee plant and no Remdesivir sales.
Besides the decline in active pharma ingredient sales, the CDMO business also lost business related to Covid products. The CDMO business still has ~Rs 700 million coming from Covid-related products, which may erode in the coming quarters.
Jubilant Pharmova’s revenue declined by 11.2% YoY and 5% QoQ, while gross margin was relatively steady at 73.3% compared to 72.8% in Q4 FY22.
Specialty pharma business saw better demand as the adverse impact of Covid-19 waned.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.